More public education and guidelines are needed to increase marijuana users’ understanding of cannabis-related driving impairment — ScienceDaily


More than half of people who take medical cannabis for chronic pain say they’ve driven under the influence of cannabis within two hours of using it, at least once in the last six months, according to a new study.

One in five of them said they’d driven while ‘very high’ in the past six months, researchers from the University of Michigan Addiction Center report in the journal Drug & Alcohol Dependence .

Lead author Erin E. Bonar, Ph.D., assistant professor of psychiatry and a practicing clinical psychologist at the U-M Addiction Treatment Services finds the results of a survey of 790 Michigan medical cannabis users troubling.

Hundreds of thousands of Americans have state approval to use medical marijuana, including nearly 270,000 in the state of Michigan, according to Statista, as of May 2018. Michigan is second only to California for the highest number of medical marijuana patients in a state.

Risky driving

Bonar says that when people drive under the influence of marijuana their reaction time and coordination may be slowed down and they could have a harder time reacting to the unexpected. If they are in a risky situation, they could be more likely to be involved in motor vehicle crash, because they would not be able to respond as quickly.

For the study, the team surveyed adults in Michigan who were seeking medical cannabis recertification or a new certification for chronic pain in 2014 and 2015. The researchers asked about respondents’ driving habits for the past six months.

Fifty-six percent of participants reported driving within two hours of using cannabis, 51 percent reported they drove while a “little high,” and 21 percent reported driving while “very high.”

“There is a low perceived risk about driving after using marijuana, but we want people to know that they should ideally wait several hours to operate a vehicle after using cannabis, regardless of whether it is for medical use or not,” Bonar said. “The safest strategy is to not drive at all on the day you used marijuana.”

There is uncertainty about how marijuana could affect driving for chronic daily users, who might have even longer-lasting effects that linger in their system, Bonar added.

Uncharted territory

To add complexity to the issue, in November Michigan voters approved the use of recreational marijuana in the state. In early December, it became legal under state law for any Michigan resident over the age of 21 to use marijuana inside a private residence, and to grow up to 12 plants for personal use. Retail sales are only allowed for those with medical marijuana cards issued by the state. Marijuana use and possession remains illegal under federal law.

In light of this policy change, Bonar says, all cannabis users need a clear understanding of the side effects of this drug.

“When it comes to driving, we haven’t yet figured out the best way to know how impaired marijuana users are at any given time,” she says. “With alcohol, you can do some quick math based on the amount you drank, and take an educated guess at your blood alcohol level. For marijuana, an estimate like this would be complicated. It’s hard to quantify because there is a lot of variation in marijuana dosing, THC potency, and route of administration. We also don’t have specific guidelines yet about when exactly it would be safe to operate a vehicle.”

Bonar says the goal of her team’s study — conducted before the passage of the ballot question that resulted in the change in state law — is to help medical marijuana users to be safer on the roads.

“We believe more research is needed to inform a larger public education effort that will help individuals understand the risks for themselves, and others, of driving while under the influence of cannabis,” she says. “It is especially needed during this time of rapid policy change as many states are determining how to manage marijuana legalization. We also need clearer guidelines about marijuana dosing and side effects with an understanding of how individual differences in things like sex and body weight interact as well.”

This study was funded by the National Institute on Drug Abuse. The lead project investigator was Mark Ilgen, Ph.D., director of UMATS. Additional study authors include James Cranford, Ph.D., Brooke Arterberry, Ph.D., Maureen Walton, M.P.H., Ph.D., and Kipling M. Bohnert, Ph.D.



Source link

MPs criticise NHS over failure to prescribe medical cannabis | Society


There is a “serious cultural block within the NHS around medical cannabis”, according to MPs.

The criticism comes after it emerged that the family of the first child to be prescribed medical cannabis after its legalisation must pay almost £10,000 a year to access the privately prescribed medicine as they follow a bureaucratic “assault course”.

The all-party parliamentary group for medical cannabis condemned the workings of the current licensing regime, saying it cannot have been what the government envisaged when they legalised medical cannabis in November.

“For Jorja [Emerson] and her family this is a great day and I commend the private consultant, supported by her private hospital, who has taken the courageous decision to prescribe a medical cannabis product which she genuinely feels is in the best interest of her patient,” said Mike Penning MP, co-chair of the group.

“But the fact remains that there is a serious cultural block within the NHS around medical cannabis. Other families, many with children just as seriously ill as Jorja, continue to face a complete block from their NHS medical teams.”

He said most families did not have the means to go private, and in any case “the number of even private clinicians willing to prescribe appears to be in low single figures”.

“I do not believe that this is what the prime minister and home secretary envisaged when they made the bold change in the law on 1 November to reschedule medical cannabis to enable consultants to prescribe it,” he added.

Calling for action from the highest levels of government to rectify a system that was “letting patients down”, co-chair Tonia Antoniazzi MP said: “The high-profile cases over the summer of Alfie Dingley and others clearly show that for some epileptic children medical cannabis containing low concentrations of THC [tetrahydrocannabinol] can be life-transforming.

“Denying parents the right for their children to try these newly available medicines is cruel. It appears that the medical profession is totally wedded to only prescribing a substance for which there is double-blind trial evidence. But there is a need for a common-sense perspective here.”

She added that many severely epileptic children were treated with conventional anti-epileptic drugs that had passed such trials, yet had severe side effects.

“To our knowledge, no one has ever died from taking THC, and in any case the concentrations that we are talking about in these medicines are very low,” she said.

Two-year-old Jorja has a rare form of treatment-resistant epilepsy that causes her to suffer from life-threatening seizures. She has been treated with a number of heavily sedative pharmaceutical drugs that consultants have said are causing long-lasting damaging effects.

She has been in intensive care twice in her life, once enduring a “status seizure” that lasted more than 17 hours, with doctors warning that she might die.

Her father, Robin Emerson, said: “This has been an assault course of bureaucracy and a rollercoaster ride of severe ups and downs. I have faced near-total opposition in my quest to get my daughter access to a medicine that is now legal in the UK and has been shown to work in similar cases. No family should have to endure what we have been through.

“Thanks to the generosity of friends and supporters I have managed to raise enough money to fund the first few months of the medicine. But at £833.75 per month I face a desperately difficult future.”



Source link

Why Diego Pellicer Worldwide Inc (OTCMKTS:DPWW) Is A Buy

By Jim Bloom Posted on December 23, 2018 ShareTweetShareEmailComments

Diego Pellicer Worldwide Inc (OTCMKTS:DPWW) has had an impressive year on the earnings front depicted by the second year of record-breaking sales.  The stock, on the other hand, has not had the best of runs having shed a substantial amount of market share.

Diego Pellicer Price Analysis

However, things are starting to look up for the stock, as the company continues to deliver robust revenue growth.  Investor’s sentiments in the stock have started inching higher depicted by high turnover in traded shares in the market.

The stock rising to six months high after underperforming for the better part of the year attests to a change in sentiments and prospects in the market.  Diego Pellicer has since bottomed out and as it, stands, looks set to start 2019 on a roll, as it continues to recoup losses accrued in 2018.

A 600% rally in the month of December alone affirms the emerging uptrend as the stock continues to turn the page after one of the worst routs in the market. After the recent surge, the stock faces immediate resistance at the $0.60 level.

Read more…

 

The 10 Best Marijuana Stocks to Buy in 2019

Dec 11, 2018, 12:07 pm EST

The 10 Best Marijuana Stocks to Buy in 2019

Although marijuana stocks have suffered sharp losses recently, the overall industry is only growing in prominence.

By Josh Enomoto, InvestorPlace Contributor

Diego Pellicer Worldwide (DPWW)

We’ve arrived at the end of our journey regarding marijuana stocks to buy in 2019. In keeping with my loose tradition, I like to throw in an extremely speculative name. And don’t roll your eyes at me: you know you want to know!

The following idea comes from an InvestorPlace reader named Anthony. He asked my opinion regarding Diego Pellicer Worldwide (OTCMKTS:DPWW). My answer to him is the same one I’m giving to you, which is that DPWW stock is extremely risky. Aside from its distressingly low trading volume and market capitalization, Diego Pellicer lacks financial strength to convincingly pull off its licensing and royalties business model.

However, I’m intrigued with its premium branding business. Not that I would know, but Diego Pellicer specializes in high-class cannabis products. As companies like Origin House and Medmen have proven, cannabis users eschew quantity for quality. That could lead to a surprising turnaround for DPWW stock.

Or you can lose every cent that you put in.

Read more…

Diego Pellicer Annual Sales and National Cannabis Accolades

Diego Pellicer Annual Sales and National Cannabis Accolades

By ME Staff -December 11, 2018

This year’s Cannabis market has been good for Diego Pellicer Worldwide Inc (OTCMKTS:DPWW). The company recently announced a 150% increase in annual sales for the fiscal year ending December 01 2018.

Projected Cannabis Market

Apparently the cannabis wing for the Colarado company, is having a great run in the growing US cannabis market even before the market fully opens up nationally. Statistics by the New Frontier Data valued the US cannabis market at $8.3 billion in 2017. However, as the nation gears to decriminalizing cannabis use, the marketed is estimated to triple at a compounded annual rate of 14.7% to about $25 billion in 2025.

Companies are in a rush to partake in the lucrative sector setting up multiple dispensaries and retail outlets.

Read more…

Diego Pellicer – Colorado Announces Second Record-Breaking Sales Year on the Heels of Two National Cannabis Business Awards

Diego Pellicer – Colorado Announces Second Record-Breaking Sales Year on the Heels of Two National Cannabis Business Awards

Diego Pellicer seeing green in advance of the holiday rush

DENVER (Dec. 10, 2018) – It is another record-breaking year for Diego Pellicer – Colorado. Diego Pellicer Worldwide, Inc. (OTCQB: DPWW), the premium marijuana brand and management company for Diego Pellicer – Colorado, today announced an outstanding 150 percent increase in gross revenue for the location from Dec. 1, 2017, to Dec. 1, 2018.

This news comes on the heels of Diego Pellicer being honored as the “Best Retail Center” and “Most Valuable Brand of the Year” at the 2018 National Cannabis Business Awards, beating out other highly regarded brands including MedMen™, Lightshade, Olio, LiveWell, The Clinic, The Green Solutions, Euflora and Kind Love.

“It’s clear that the multi-billion dollar cannabis market is growing and so is Diego Pellicer,” said Ron Throgmartin, CEO of Diego Pellicer Worldwide, Inc. “Our premium brand featuring the finest products, exceptional service in an approachable, world-class environment, along with our management leadership and expertise has proven successful.”

Diego Pellicer is actively pursuing opportunities to expand into new markets and retail locations including California. Interested parties are encouraged to connect via the company’s website at www.Diego-Pellicer.com or call Nello Gonfiantini at 775-690-2188.

CONTACTS:

Suzanne Herrick, Fedoruk & Associates, Inc., 612-247-3079, suzanne@fedorukinc.com

Nello Gonfiantini, Diego Pellicer Worldwide, Inc., 775-690-2188, nello@diego-pellicer.com

Neil Demers, Diego Pellicer – Colorado, 720-937-9073, neil@diego-pellicer.com

URLS:                      www.diego-pellicer.com

About Diego Pellicer Worldwide, Inc. (OTCQB: DPWW)

Diego Pellicer Worldwide, Inc. is the premium marijuana brand and management company. In addition to its branded locations in Colorado and Washington, the company actively seeks to develop and manage high-end, turnkey cannabis retail stores. When federally legal, DPWW is positioned to become a national, vertically integrated marijuana company. To learn more about how to become a branded Diego Pellicer retailer, cultivator or investor visit www.Diego-Pellicer.com.

Safe Harbor Statement

Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

# # #

Diego Pellicer Receives National Honors for the “Most Valuable Brand of the Year” and the “Best Retail Center” at the 2018 National Cannabis Business Awards

FOR IMMEDIATE RELEASE

Diego Pellicer Receives National Honors for the “Most Valuable Brand of the Year” and the “Best Retail Center” at the 2018 National Cannabis Business Awards

DENVER (Dec. 6, 2018) – Diego Pellicer Worldwide, Inc. (OTCQB: DPWW) the premium marijuana brand and management company, today announced that Diego Pellicer took top national honors at the 2018 Cannabis Business Awards, receiving two CBA Globe awards in the sought-after categories of retail and branding.

Diego Pellicer was awarded “Most Valuable Brand of the Year” beating out tough national competition including MedMen™, The Clinic, Lightshade and Olio. Diego was also honored as the “Best Retail Center” for the second year in a row, defeating other highly regarded names including LiveWell, The Clinic, The Green Solutions, Euflora and Kind Love.

“The Cannabis Business Awards are the most prestigious awards in the multi-billion dollar cannabis industry. This is such an honor for Diego Pellicer,” said Ron Throgmartin, CEO of Diego Pellicer Worldwide, Inc. “We’ve known the power of Diego’s premium brand and progressive business model – these two CBA Globe awards demonstrate that Diego customers appreciate the world-class experience that Diego Pellicer provides and the industry recognizes our leading mana ement model.”

CBA Globes Presented at Exclusive Event in Colorado

The CBA Globe awards were presented to Throgmartin and Neil Demers, CEO of Diego Pellicer – Colorado, at an exclusive evening event at the Hilton Ballroom in downtown Denver on December 5, 2018. The red carpet event was packed with the top business executives, trailblazers and thought leaders in the cannabis industry.

“This is monumental. These awards are the pinnacle of the profession, recognizing the best of the best,” said Demers. “The premium Diego Pellicer branded stores feature the finest products, hospitality level quality service in an approachable, world-class environment. We are truly honored to have been nominated by so many and to receive two prestigious CBA Globe Awards.”

Since 2011, Chloe Villano and Clover Leaf have been producing the Cannabis Business Awards to honor cannabis professionals deserving of historical recognition and esteemed accolades for industry progression and innovation. The national Cannabis Business Awards are presented to cannabis industry businesses, individuals and organizations in both medical and recreational sectors, as well as ancillary industries.

CONTACTS:

Suzanne Herrick, Fedoruk & Associates, Inc., 612-247-3079, suzanne@fedorukinc.com

Nello Gonfiantini, Diego Pellicer Worldwide, Inc., 775-690-2188, nello@diego-pellicer.com

Neil Demers, Diego Pellicer Colorado, 720-937-9073, neil@diego-pellicer.com

URLS:                      www.diego-pellicer.com; www.cbaglobes.com

About Diego Pellicer Worldwide, Inc. (OTCQB: DPWW)

Diego Pellicer Worldwide, Inc. is the premium marijuana brand and management company. In addition to its branded locations in Colorado and Washington, the company actively seeks to develop and manage high-end, turnkey cannabis retail stores. When federally legal, DPWW is positioned to become a national, vertically integrated marijuana company. To learn more about how to become a branded Diego Pellicer retailer, cultivator or investor visit www.Diego-Pellicer.com.

Safe Harbor Statement

Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

# # #